BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 9, 2009--
Bruker Corporation (NASDAQ: BRKR) today announced that its Board of
Directors has appointed Bill Knight to Chief Operating Officer (COO) and
Brian Monahan to Chief Financial Officer (CFO), with an effective date
of February 1st, 2010. Presently, Bill Knight is serving as
CFO, and Brian Monahan is serving as Chief Accounting Officer of Bruker
Corporation.
Frank Laukien, Bruker’s President and CEO, stated: “Bruker has a 49 year
proud history of technology leadership and customer-focused product
innovation. Going forward, we believe that the combination of continued
innovation and an increased focus on operational excellence will drive
margin expansion, balance sheet metrics and cash flow for increasing
shareholder value. In order to drive our operational excellence
initiative, we have created the new position of Chief Operating Officer
at Bruker Corporation.”
He continued: “Today, we are very pleased to announce the promotion of
two extremely capable individuals to expanded responsibilities. Over the
past five years, Bill Knight has demonstrated strong financial and
operational leadership at Bruker, and in his newly-created COO role Bill
will lead and fully focus on our operation excellence initiative. Brian
Monahan has been a key leader and contributor in our finance
organization over the past five years, and we believe he is an excellent
choice to succeed Bill as our CFO.”
Biographies
Mr. Knight joined Bruker Corporation as CFO and Treasurer in October
2004. At Bruker, Mr. Knight is also the President of the Bruker
Detection business in the United States. Before joining the Company,
Mr. Knight served as an operations-focused CFO in several public
companies, and was a founder of ATI Technologies, an analytical
instruments company, where he had both financial and operational
responsibilities. Mr. Knight served as CFO of Anika Therapeutics, Inc.,
from 2002 to 2004. He served as CFO of Zycos, Inc., a developer of
DNA-based therapeutic products, from 2000 to 2002, and as CFO of NMT
Medical, Inc., a provider of cardiovascular and neurological medical
devices, from 1998 to 2000. Mr. Knight is a Certified Public Accountant
and holds a B.B.A. in Accounting from the University of Wisconsin.
Mr. Monahan joined Bruker Corporation as the Corporate Controller in
April 2004 and was appointed Chief Accounting Officer and Vice President
of Finance in March 2009. In addition to his corporate responsibilities,
Mr. Monahan has served in both financial and operational roles in the
Bruker Daltonics division, where he has been an Executive Vice President
of Bruker Daltonics since November 2006 and General Manager of the
Americas since July 2008. From January 2005 to November 2006,
Mr. Monahan was Vice President of Finance for Bruker Daltonics, and from
July 2004 to January 2005 he was Assistant Vice President of Finance for
Bruker Daltonics. Before joining the Company, from 2002 through 2004,
Mr. Monahan served as the Manager of Accounting and Financial Reporting
at Fisher Scientific International, Inc., and as an audit manager for
PricewaterhouseCoopers LLP from 1999 through 2002. Mr. Monahan is a
Certified Public Accountant and holds a B.S. in Accounting from the
University of Massachusetts.
ABOUT BRUKER CORPORATION
Bruker Corporation is a leading provider of high-performance scientific
instruments and solutions for molecular and materials research, as well
as for industrial and applied analysis. For more information about
Bruker Corporation, please visit www.bruker.com.
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to risks and uncertainties, that could
cause actual future results to differ materially from those projected
including, but are not limited to, risks and uncertainties relating to
adverse changes in conditions in the global economy and volatility in
the capital markets, the integration of businesses we have acquired or
may acquire in the future, changing technologies, product development
and market acceptance of our products, the cost and pricing of our
products, manufacturing, competition, dependence on collaborative
partners and key suppliers, capital spending and government funding
policies, changes in governmental regulations, realization of
anticipated benefits from economic stimulus programs, intellectual
property rights, litigation, and exposure to foreign currency
fluctuations and other risk factors discussed from time to time in our
filings with the Securities and Exchange Commission. These and other
factors are identified and described in more detail in our filings with
the SEC, including, without limitation, our recent Proxy Statements on
Schedule 14A, our annual report on Form 10-K for the year ended December
31, 2008, our most recent quarterly reports on Form 10-Q and our current
reports on Form 8-K. We expressly disclaim any intent or obligation to
update these forward-looking statements other than as required by law.
Source: Bruker Corporation
Bruker Corporation
Stacey Desrochers, +1-978-663-3660, ext. 1115
Director
of Investor Relations
stacey.desrochers@bruker.com
View printer-friendly version